本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。 關閉
The 10th edition of the Goodman Magic Mile Charity Run returns to the Goodman Interlink facility in Tsing Yi on Sunday, 9 March 2025 The event is open to the public, sports enthusiasts and corporate sponsors and will raise vital funds for Habitat for Humanity Hong Kong Registration closes on 22 January 2025 HONG KONG, Dec. 4, 2024 /PRNewswire/ -- On Sunday, 9 March 2025, the Goodman Magic Mile Charity Run will celebrate its 10th anniversary where it all began, at the iconic ramp in Goodman Interlink, Tsing Yi. Goodman Magic Mile 2025 This milestone event, in partnership with Habitat for Humanity Hong Kong, will bring the community together once again to support Habitat's 'Project Home Works' program. This initiative aims to improve the living conditions of the elderly and low-income families living in substandard housing in Hong Kong. Participants can choose from two races: Magic Mile Classic: A one-mile run or walk up Goodman Interlink's ramp, open to families and corporate teams Magic Mile Challenge: A four-mile race where individual participants run two complete laps of the entire ramp. This year, the Goodman Magic Mile Charity run introduces a new family-friendly component - the Little Fashion Icons Contest. Children under the age of 12 are welcome to dress up creatively and comfortably for their run, for the chance to win amazing prizes. Adding to the vibrant atmosphere, Goodman's customers Vitasoy and HFT will support as beverage sponsors, while NOC Coffee Co. will keep the adults energised with barista-made coffee. Interlink café partner Maxim's will host a pop-up booth providing complimentary food and beverages. Additionally, there will be a fundraising sausage sizzle inspired by the Australian BBQ tradition. While the atmosphere will fun, the event raises money for an important cause. "In Hong Kong, many vulnerable families, including the elderly and people with disabilities, continue to live in unsafe and inadequate housing," said Jo Hayes, Chief Executive Officer, Habitat for Humanity Hong Kong. "Through our partnership with Goodman and the Magic Mile Charity Run, we are able to bring tangible improvements to their lives by funding essential home repairs and renovations. Every step taken and every donation made helps build a more hopeful, resilient future for those in need. We are excited to once again join forces with Goodman and the community for this impactful event". Deputy CEO of Goodman Group Greater China, Andrew McGregor, said: "We are determined to make the 10th Goodman Magic Mile Charity Run our best one yet. This event brings our community of partners and sponsors together in Hong Kong to raise funds for a worthy cause. We are proud to partner once again with Habitat to help meet the essential needs of vulnerable local families. We look forward to welcoming customers, corporate sponsors and their families, as well as our Goodman team to this milestone event, so please register now and come join the fun." The event is returning to Goodman Interlink – one of the company's landmark logistics facilities. The property is currently undergoing a facade upgrade, completing in early 2025, to be more sustainable and resilient to local weather conditions. Event details: Date: Sunday, 9 March 2025 Time: 8:30am – 12:00pm Location: Goodman Interlink, 39 Tsing Yi Road, Tsing Yi, New Territories, Hong Kong SAR, China Free shuttle bus service: Complimentary shuttle bus services will operate every fifteenminutes between Tsing Yi MTR station, Kwai Fong MTR stationand Goodman Interlink. 1. Tsing Yi MTR Station Exit C <> Goodman Interlink From 7:45am to 11:45am 2. Kwai Fong MTR Station Exit C <> Goodman Interlink From 7:55am to 11:55am Event site: https://hk.goodman.com/goodman-magic-mile Registration site: Magic Mile 2025 Sponsorship Registration Charity Partner: https://habitat.org.hk/ Registration deadline: Wed, 22 January, 2025 -ENDS- For further information, please contact: Wendy Cheung, Marketing ManagerWendy.Cheung@goodman.comPh: +852 6111 1641 Michelle Chaperon, Head of Corporate CommunicationsMichelle.Chaperon@goodman.com Ph: +61 (0) 416 285 907 About Goodman Goodman Group is a provider of essential infrastructure. It owns, develops and manages high quality, sustainable logistics properties and data centres in major global cities, that are critical to the digital economy. Goodman has operations in key consumer markets across Australia, New Zealand, Asia, Europe, the United Kingdom, and the Americas. Goodman Group, comprised of the stapled entities Goodman Limited, Goodman Industrial Trust and Goodman Logistics (HK) Limited, is the largest property group on the Australian Securities Exchange (ASX: GMG), a top 15 entity by market capitalisation, and one of the largest listed specialist investment managers of industrial property globally The Group's property portfolio includes logistics and distribution centres, warehouses, light industrial, multi-storey industrial, business parks and data centres. Goodman takes a long-term view, investing significantly alongside its capital partners in its investment management platform and concentrating the portfolio where it can create the most value for customers and investors.For more information visit: www.goodman.com
PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, today announced that it has entered into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324. Under the agreement, DualityBio will grant GSK an exclusive option to obtain a license to develop and commercialize DB-1324 worldwide (excluding mainland China, Hong Kong, and Macau) (the "Option"). DB-1324 is an ADC candidate built with DualityBio's proprietary and clinically validated Duality Immune Toxin Antibody Conjugate (DITAC) platform. The molecule, currently in preclinical development, leverages DualityBio's DITAC platform against a gastrointestinal (GI) cancer target. There is high unmet medical need for patients with GI cancer as it represents 35% of all cancer-related deaths and approximately 26% of the global cancer incidence.[1] This ADC molecule has the potential to unlock multiple combination therapy opportunities to strategically complement GSK's oncology portfolio. Under the terms of the agreement, GSK will pay $30 million upfront and additional pre-option milestone payments to obtain an exclusive option for exclusive worldwide rights for DualityBio's ADC (excluding China's mainland, Hong Kong, and Macau). Upon GSK exercising the Option, DualityBio will receive an option exercise fee as well as potential development, regulatory and commercial milestone payments totalling up to $975 million. Upon commercialisation, GSK will pay tiered royalties on DB-1324's global net sales outside mainland China, Hong Kong, and Macau. GSK will receive royalties on net sales in mainland China, Hong Kong and Macau. Hesham Abdullah, SVP, Global Head Oncology, R&D, GSK, said: "GSK has built a portfolio of novel antibody-drug conjugates underpinned by our deep expertise in tumour cell-targeting mechanisms. Given the unique ability of ADCs to address certain targets on tumour cells while sparing healthy ones, we are confident in our strategic focus on this modality as it could advance new therapeutic treatments for the most challenging tumour types." John Zhu, Chief Executive Officer of Duality Biologics, said: "DualityBio is dedicated to becoming a leading global next-generation ADC company. We are very glad to have entered into this agreement with GSK. Through this collaboration, we will work together to advance our innovative ADC program in gastrointestinal cancer to address unmet medical needs. DualityBio's unique and validated ADC technology platform can continue to empower more partners around the world and provide innovative treatment options for global patients." About Duality Biologics Duality Biologics ("DualityBio") is a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and beyond. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Based on deep understanding of diseases, DualityBio has built a robust pipeline of ADCs, including several candidates in clinical stage. DualityBio has multiple ongoing global multi-regional clinical trials (MRCTs) across 17 countries with over 1,000 patients enrolled. In addition, DualityBio is leveraging its novel protein engineering and unique ADC technologies to develop the next generation of "Super ADCs", such as bispecific ADCs, ADCs with novel MOA payload and antibody-immune modulator-conjugates. DualityBio Enquiries Media/Investor Relations: IR@dualitybiologics.com References [1] Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al.Global burden of 5 major types of gastrointestinal cancer. Gastroenterology, 159(1):335–349.e15.
CARBONCO and Genesis Fertilizers Limited Partnership ("Genesis Fertilizers") achieves a final agreement for the integration of CARBONCO's cutting-edge carbon capture technology CARBONCO's technology will provide post-combustion carbon capture and compression/dehydration solution for Genesis Fertilizers' CCS Project SEOUL, South Korea, Dec. 3, 2024 /PRNewswire/ -- CARBONCO Pte. Ltd., a leading provider of decarbonization technology solutions, has officially entered into a License Agreement as the carbon capture technology licensor with Genesis Fertilizers, making a significant step toward the development of Canada's proposed first low-carbon urea nitrogen fertilizer facility. This state-of-the-art proposed project will ensure a reliable and stable supply of clean fertilizer for Genesis Fertilizers' farming partners and the broader North America agriculture industry. From left to right: Jason Mann, CEO of Genesis Fertilizers; Tamara Mawhinney, Canadian Ambassador to Korea; and Sangmin Lee, CEO of CARBONCO, at the Signing Ceremony held at the Canadian Embassy to Korea on November 20. The proposed facility will capture approximately 800,000 tons of CO2 annually, eliminating 95% of the carbon emissions generated by the plant. Captured CO2 will be delivered via pipeline in a compressed and dehydrated form to a storage hub located 10 miles from the facility for permanent sequestration. Genesis Fertilizers' production complex is set to be constructed in Belle Plaine, Saskatchewan, Canada, and is targeted to commence its commercial operations by 2029. The License Agreement signing ceremony was held in Schofield Hall at the Embassy of Canada to Korea on November 20, 2024, at 14:00 (UTC+9). The ceremony marked the commitment of both parties to collaborate on developing the world's lowest carbon foot-print nitrogen facility, utilizing cutting-edge amine-based carbon capture technology. Distinguished attendees included Mr. Jason Mann, President and CEO of Genesis Fertilizers, Dr. Sangmin Lee, CEO of CARBONCO, and their respective teams. Notably, the ceremony was hosted by the Embassy of Canada to Korea with Ms. Tamara Mawhinney, Ambassador of Canada to Korea gracing the occasion with her presence and delivering a congratulatory speech to commemorate the license agreement. Dr. Sangmin Lee, CEO of CARBONCO, said "CARBONCO has been collaborating with top global players on carbon capture projects. As always, CARBONCO's team will give its full commitment to realizing Genesis Fertilizers' ultimate goal. CARBONCO is confident that our efforts will bolster Genesis Fertilizers' proposed facility in achieving smooth commercialization. CARBONCO will do its best to strengthen this valuable partnership." Mr. Jason Mann, CEO of Genesis Fertilizers, said "By capturing 95 percent of the CO2 emissions, we plan to establish one of the world's cleanest ammonia plants powered by the Haber-Bosch process. Our unique model allows farmer-investors to pay market price for the fertilizer and benefit from year-end partnership distributions. Additionally, low carbon fertilizer could further yield premium prices for crops like wheat and corn, aligning with food companies' ESG goals. This fosters a sustainable and profitable agricultural supply chain." About CARBONCO CARBONCO Pte. Ltd. is a total technology provider for post combustion carbon capture and compression & dehydration. CARBONCO has been actively expanding its international business, and it successfully covers a wide range of services, from consulting service to technology licensing services and business development. CARBONCO has standardized its capability to capture carbon dioxide up to 3,000TPD per single train across various industries. About Genesis Fertilizers Genesis Fertilizers is proposing to finance, design and construct a new, highly efficient nitrogen fertilizer production and distribution system that serves today's modern farmer. This will be comprised of a central production facility constructed near low-cost raw materials serving a Western Canadian network of strategically located farmer-centric distribution centers. Genesis Fertilizers is a privately held limited partnership and its securities do not trade on any exchange. ContactsCARBONCO Pte. LtdSangho Lee+82-2-369-5812sh@carbonco.com Genesis FertilizersBreanne Baker(587) 433-8177bbaker@genesisfertilizers.com
MANILA, Philippines, Dec. 3, 2024 /PRNewswire/ -- Ayala Healthcare Holdings, Inc. (AC Health), in partnership with the U.S. Agency for International Development (USAID), is leading the private sector's efforts to fight the HIV epidemic in the Philippines by improving access to stigma-free care and lifesaving services. [Left to Right] Andrea Halverson, USAID Health Office Director; MaryKay Carlson, US Ambassador to the Philippines; Fernando Zobel de Ayala, AC Health Chairman; Tracy Hawry, Deputy Director of the Office of Health, USAID Philippines and Mongolia; Ryan Washburn, USAID Mission Director; Paolo Borromeo, AC Health President & CEO. The partnership was sealed in time for World AIDS Day, whose theme "Collective Action: Sustain and Accelerate HIV Progress," underscores the importance of collaboration to overcome this health challenge. AC Health will leverage its unique ecosystem to develop, test, and scale approaches to improving and expanding HIV care and prevention services in the Philippines. AC Health will onboard qualified health service providers on the KonsultaMD platform and expand HIV awareness and screening services beyond health facilities. It will also import essential medicines and other lifesaving technologies through units IE Medica and MedEthix and make these commercially available through Generika Drugstore. An important ally in the Philippines' fight against HIV, USAID will support community engagement, provide technical assistance to Healthway Medical Network, and introduce private sector models for HIV service delivery. USAID will also train healthcare providers, share research, expand telehealth access through KonsultaMD, and coordinate with partners to provide free HIV self-testing kits. "Our mission at AC Health is to make quality and affordable healthcare accessible to more Filipinos. Through our partnership with USAID, our dedicated teams at Healthway Medical Network, KonsultaMD, and Generika Drugstore have been equipped with specialized training to serve key populations affected by HIV. This collaboration brings us closer to bridging gaps in HIV prevention and testing, ensuring these critical services reach more communities nationwide," said AC Health Chairman Fernando Zobel de Ayala. The partnership is a key initiative to support the Philippines in addressing one of the fastest-growing HIV epidemics in Southeast Asia. AC Health's participation also highlights its growing role in responding to public health challenges in the country. AC Health, in partnership with Publicis Groupe Philippines and the People Management Association of the Philippines, is also leading the "Working with Cancer Pledge" in the country. This initiative is a global movement to raise awareness and support for people struggling with cancer in the workplace. Since its launch in 2023, hundreds of companies globally have been transformed into inclusive workplaces for employees dealing with cancer. AC Health, a wholly-owned subsidiary of Ayala Corporation, aims to provide every Filipino accessible, affordable, and quality healthcare. Its portfolio includes Generika Drugstore, the pioneer in generic retail pharmacies; St. Joseph Drug, a leading retail drugstore chain in North Luzon; IE Medica and MedEthix, a major pharmaceutical importer and distributor; Healthway Medical Network, a network of multi-specialty clinics, ambulatory centers, and full-service hospitals; and KonsultaMD, a healthcare aggregator app that offers online consultations, medicine delivery, and clinic and diagnostic booking. Through its three pillars—pharma, hospitals and clinics, and digital health—AC Health creates a seamless and integrated healthcare ecosystem for the Filipino patient. About Ayala Corporation For 190 years, Ayala Corporation has been building businesses that enable people to thrive. Ayala, currently one of the largest conglomerates in the Philippines, has meaningful presence in real estate, banking, digital solutions, and renewable energy. It likewise has a growing presence in healthcare, mobility, and logistics as well as investments in industrial technologies, education, and other ventures. Ayala manages its corporate social responsibility initiatives through Ayala Foundation. Visit our website at https://ayala.com and by follow us on LinkedIn to learn more about the company.
Over 30 million GoPay customers can now access Oona Indonesia's affordable health insurance solutions, exclusively on GoPay Asuransi Oona Indonesia continues to boost insurance penetration through strategic digital partnerships and digital innovations JAKARTA, Indonesia, Dec. 3, 2024 /PRNewswire/ -- Oona Insurance Indonesia, a leading digital general insurer in Indonesia, has reached a new milestone by partnering with Indonesia's top digital payment platform, GoPay and leading insurance brokerage firm, Prodigi to expand access to affordable and accessible health insurance solutions for Indonesians. Over 30 million GoPay users can now easily buy simplified health insurance products via GoPay Asuransi, the payment app's first insurance platform with Oona Indonesia as its exclusive insurer. This collaboration represents a pivotal step in Oona Insurance's mission to solidify its presence in the retail health insurance sector. By integrating with GoPay's platform, Oona Indonesia has simplified the insurance purchase process, making it seamless and user-friendly. With GoPay Asuransi, users can quickly select and purchase health insurance by answering a few simple health questions. Personal details are automatically populated from their GoPay profile, eliminating repetitive data entry and ensuring a seamless, hassle-free experience. Payments are seamlessly processed via GoPay for maximum convenience. "This partnership underscores our commitment to leveraging digital innovation to expand our ecosystem and make insurance affordable and accessible to millions of Indonesians. By collaborating with trusted partners like GoPay and Prodigi, we are breaking barriers to insurance access with affordable and simplified products designed for today's digital consumers. GoPay Asuransi fits effortlessly into everyday financial activities, making insurance more accessible to Indonesians than ever before." said Manik Bucha, Group Chief Underwriting Officer, Oona Insurance. "We remain bullish on our growth and will continue forging digital partnerships across different categories to drive insurance penetration and deliver value to our customers," added Manik Bucha, Group Chief Underwriting Officer of Oona Insurance. Kiki Apriyani, Head of Marketing Money Management of GoPay added, "We are excited to partner with Oona Insurance and Prodigi to bring insurance products directly to the GoPay platform, reflecting our commitment to addressing societal challenges and driving financial inclusion. This collaboration is a step toward empowering Indonesians with equitable access to essential financial services. By making health insurance products more accessible and affordable, we aim to enhance financial resilience for GoPay users across Indonesia and look forward to exploring more opportunities with Oona Indonesia to deliver innovative, impactful solutions in the future." GoPay users can choose from GoPay Asuransi two plans powered by Oona Indonesia: Critical Illness Insurance starting at Rp5,000, providing a lump-sum cash payout upon diagnosis of heart attack and cancer with benefits up to Rp100 million, and Health Insurance starting at Rp60,000, offering coverage for ICU, inpatient and outpatient care across 1,300+ hospitals and clinics with an annual limit up to Rp100 million. About Oona Insurance Headquartered in Singapore, Oona Insurance is the leading digital general insurer in Southeast Asia, backed by global private equity firm Warburg Pincus. Established in 2022, Oona Insurance aims to become the general insurer of choice for both partners and customers through a buy-and-build strategy, leveraging the pillars of superior customer service, advanced technology and a well-established brand across Southeast Asia. The firm currently operates in two markets in the region: Indonesia and the Philippines. In Indonesia, Oona operates through its licensed general insurance entity, PT Asuransi Bina Dana Arta, Tbk. Oona Indonesia, the new unified brand of this entity, offers quality products and services since early 2023, serving as a solid foundation for Oona Insurance's expansion across Southeast Asia's fast-growing insurance market. Oona Indonesia is licensed and supervised by Indonesia Financial Services Authority (Otoritas Jasa Keuangan). For more information on Oona Insurance, please visit: www.oona-insurance.com
JAKARTA, Indonesia, Dec. 3, 2024 /PRNewswire/ -- IAT (Singapore) Technology Pte. Ltd. (IAT), a leading provider of professional Near-Infrared (NIR) analysis products and services, has signed a Memorandum of Understanding (MoU) with the Aspekpir (Aspek Perkebunan Inti Rakyat or Nucleus-Plasma Plantation Partnerships). This partnership aims to revolutionize quality analysis in the palm oil industry. With its flagship product, the IAS-6100, IAT introduces advanced technology capable of delivering real-time data in less than two minutes, offering highly accurate assessments of oil palm fruit and its by-products. IAT Inks MoU with Aspekpir Indonesia to Enhance Quality Analysis for the Local Palm Oil Industry Currently, Aspekpir has 15 Regional Representative Councils (Dewan Perwakilan Daerah, DDP) in Indonesia, with 9 of these councils located in palm oil-producing provinces with PIR schemes. Additionally, IAT has formed partnerships with 7 of these provinces, namely Aceh/Bengkulu/Lampung, North Sumatra, Riau, Jambi, West Kalimantan, East Kalimantan, and Central Kalimantan. As a major contributor to the global palm oil supply, Indonesia's industry holds significant importance in food production, biofuels, and cosmetics. IAT offers palm oil quality detection tools to analyse various materials such as palm fruit, FFB, EFB, CPO/PKO, palm kernels, pressed fiber, and production waste. One of the outstanding tools is the IAS-6100, which is compact and portable, making it ideal for diverse settings, including offices, production sites, laboratories, and plantations. IAT's entry into the palm oil industry this year represents a strategic move to enhance quality testing methods, replacing traditional processes with faster and more efficient alternatives. "Before entering the oil palm sector, we conducted extensive research to determine precise testing parameters. With advanced research capabilities and experienced personnel, the IAS-6100 achieves an accuracy rate exceeding 95%. Regular calibration can further enhance this accuracy to 100%. The tool enables quick decision-making at the management level by delivering results in a matter of minutes," said Edi Hariyanto, Indonesia Sales Manager at IAT. The IAS-6100 employs cutting-edge technology, including a spectral engine, DMD digital micromirror scanning, and next-generation circuit boards. Its features include compact design for flexibility, fast and non-destructive testing for precise data, wide applicability across multiple industries, user-friendly operation with minimal manual intervention, and environmentally friendly testing processes that eliminate the need for chemical pre-treatment. Traditional quality analysis in laboratories can be time-consuming, with oil content testing alone requiring 15 to 16 hours. The IAS-6100 reduces this time dramatically, delivering results in just two minutes per sample. Its multi-parameter analysis capability allows a single device to perform multiple tests without compromising sample integrity. By removing the need for chemical reagents, the device also supports green production practices and aligns with sustainability goals. IAT's service network spans across Southeast Asia and provides customized solutions, installation, training, application support, and after-sales services. The company's Sales Engineers are active in key palm oil regions such as Sumatra and Kalimantan, and future plans include collaborations with equipment distributors and agricultural machinery providers to further expand its reach. IAT also intends to strengthen its presence in both the Indonesian and Malaysian markets by demonstrating the IAS-6100's capabilities to stakeholders such as PKS, GAPKI, and APKASINDO through seminars and direct engagements. Edi emphasized the importance of collaboration with local agencies, noting that IAT will host seminars in December in Medan in partnership with Disbun Medan, Riau, and Palembang. Additionally, IAT will work with the Directorate General of Plantation and the Ministry of Agriculture's Directorate of Seed Development to conduct a seminar in Bogor focused on testing plantation seeds. Moving forward, IAT aims to support the modernization of Indonesia's palm oil sector while promoting sustainable practices. For more information, visit www.iat-tech.com.
A12 藝術空間
Licensing/marketing agreements
請先登入後才能發佈新聞。
還不是會員嗎?立即 加入台灣產經新聞網會員 ,使用免費新聞發佈服務。 (服務項目) (投稿規範)